ArticleBMC women's health2026
Estrogen receptor (ESR) 1 promotes uterine leiomyoma cell proliferation by enhancing mitochondrial energy metabolism via Wnt/β-catenin pathway activation.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Ferroptosis in Diabetes Pathogenesis: Therapeutic Implications of Hydrogen Sulfide and Its Reactive Metabolites.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperactive mitochondrial energy metabolism supports the rapid proliferation of uterine leiomyoma cells. Estrogen receptor (ESR)-1 is associated with mitochondrial functions and the Wnt/β-catenin pathway; however, its regulatory roles in this pathway remain unclear. Therefore, we aimed to assess whether ESR1 enhances mitochondrial energy metabolism and regulates ferroptosis by activating the Wnt/β-catenin pathway.
methodsUsing the GSE593 dataset from the Gene Expression Omnibus and GeneCards databases, we identified ESR1 as the key hub gene. ESR1 knockdown rat uterine leiomyoma cell model (ELT3) was constructed to evaluate the cell proliferation, ferroptosis, and mitochondrial function changes. Moreover, Wnt/β-catenin pathway activator 1, AG1 was used to verify the regulatory relationship between ESR1 and this pathway.
resultsBioinformatics analysis identified 22 mitochondria-related differentially expressed genes. Among these, ESR1 exhibited the highest connectivity in the protein–protein interaction network (degree = 5). ESR1 was highly expressed in ELT3 cells. ESR1 knockdown significantly inhibited cell proliferation, induced ferroptosis (increased the Fe²⁺ and malondialdehyde levels and caused disappearance of mitochondrial cristae), and reduced the mitochondrial membrane potential and levels of key energy metabolism-related proteins. Mechanistically, ESR1 knockdown inhibited the Wnt/β-catenin pathway (downregulated the β-catenin and p-GSK-3β(Ser9)/GSK3β levels). However, AG1 reversed these effects, restoring cell proliferation and mitochondrial functions.
conclusionsOverall, ESR1 enhanced mitochondrial oxidative phosphorylation by activating the Wnt/β-catenin signaling pathway, driving uterine leiomyoma cell proliferation. However, our findings suggest that its knockdown induces ferroptosis in leiomyoma cells, revealing a new strategy to prevent uterine leiomyoma recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.